Search for: "David Takeda"
Results 1 - 16
of 16
Sorted by Relevance
|
Sort by Date
5 Feb 2008, 11:03 am
Heintz of Porter Wright Morris & Arthur in the firm's Nanotechnology Law Report Podcast of Maniloff's top ten insurance coverage cases of 2007 - Portland attorney David Rossmiller of Dunn Carney in the firm's Insurance Coverage Law Blog Implications of the Amgen-Takeda deal - Management consultant Cliff Mintz of BioInsights Inc. in his Bio Job Blog [read post]
28 Jul 2015, 11:52 am
Takeda Pharms. [read post]
20 Aug 2010, 1:40 pm
David Graham, an F.D.A. medical officer, made an impassioned presentation at the advisory hearing arguing that the study should be stopped because thousands of patients in the trial were being exploited. [read post]
21 Oct 2014, 9:05 pm
David Kessler, former FDA chief, as "plaintiff's mouthpiece"; earlier on Actos/Takeda case] “Third-Party Bad Faith Claims Add $800M to Florida Auto Insurance Costs: IRC” [Insurance Journal] Discussion of proposals to change contributory negligence for bicyclists in D.C., mucho comments [Greater Greater Washington] “Missouri Supreme Court Invalidates State’s Legislative Cap on Punitive Damages” [Mark Behrens] Tweet Tags:… [read post]
16 May 2019, 5:52 am
Takeda Pharms. [read post]
30 Jul 2007, 2:59 am
David Graham.The document was distributed at the onset of a daylong meeting of a joint panel of outside experts convened to consider whether the drug should be restricted to use in select patients and branded with prominent warnings or removed altogether from sale. [read post]
7 Dec 2023, 1:47 pm
Lundbeck A/S and its licensee Takeda relating to the antidepressant drug Trintellix (vortioxetine). [read post]
15 Feb 2024, 9:05 pm
Despite FDA’s initial rejection in 2021, Takeda resubmitted its application after analyzing previous clinical studies and submitting new data. [read post]
7 Jan 2020, 7:26 am
No Arrow declaration was granted. (6) Enablement In Takeda v Hoffmann-La Roche [2019] EWHC 1911 , the UK judge (Birss J) ruled about enablement. [read post]
16 Mar 2021, 6:00 am
See, e.g., Takeda Pharm. [read post]
7 Nov 2008, 3:42 am
No problem: In re Ciprofloxacin Hydrochloride Antitrust Litigation (Patent Baristas) US: FTC Commissioner speaks out on follow-on biologics – current initiatives and long-term goals (FDA Law Blog) US: Hatch-Waxman Act-related lawsuits likely to drop, but generic companies may start to challenge biotechnology patents, says David Pritikin (Law360) US: Sequenom sues rival genetic research company Ibis Biosciences alleging infringement of DNA analysis patents (Law360) … [read post]
18 Mar 2010, 2:30 am
: The Medicines Company v David Kappos et al (FDA Law Blog) Advate (Antihemophilic) – US: False marking complaint filed in N D Illinois: Simonian v. [read post]
26 Jan 2010, 7:06 am
Gleacher Distinguished Service Professor of Finance, University of Chicago Booth School of Business, USA Nouriel Roubini ** Chairman, Roubini Global Economics Monitor, USA David M. [read post]
3 May 2014, 8:56 am
Sutherland, David Spiegelhalter & Mark Burgman, “Policy: Twenty tips for interpreting scientific claims,” 503 Nature 335, 337 (2013). [read post]
11 Apr 2008, 9:00 am
’ – 18 – 22 June, US/Alaska: (Public Knowledge), Center for IP 8th Annual IP Symposium – 28-30 May, Maryland US: (Public Knowledge), University of Maastricht: Conference on public health, innovation and intellectual property – 15 April, Maastricht (Netherlands): (IPR-Helpdesk), NLSIU Symposium: ‘Challenges to India’s patent regime’ – 12-13 April: (Spicy IP), Anti-counterfeiting and brand… [read post]
19 Jun 2022, 4:44 pm
Perhaps the most important point of this law review article, “Differential Etiology: Inferring Specific Causation in the Law from Group Data in Science,” is that general causation is necessary but insufficient, standing alone, to show specific causation. [read post]
